Effects of kidney transplant on rocuronium dosage
Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft During Kidney Transplantation
This study is testing how kidney transplants affect the right dosage of a muscle relaxant used during surgery to help patients recover faster.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT02827435 on ClinicalTrials.gov |
What this trial studies
This study investigates how the reperfusion of a renal graft during kidney transplantation affects the pharmacokinetic and pharmacodynamic parameters of rocuronium, a muscle relaxant used during surgery. By evaluating changes in urine output and other factors during the transplantation process, the study aims to develop a pharmacokinetic-pharmacodynamic model that can guide the appropriate dosing of rocuronium. The goal is to ensure stable muscle relaxation and facilitate faster recovery for patients undergoing this procedure.
Who should consider this trial
Good fit: Ideal candidates for this study are patients scheduled for elective living donor kidney transplantation who have end stage renal disease and are experiencing oliguria or anuria.
Not a fit: Patients with underlying neuromuscular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to optimized dosing of rocuronium, improving surgical outcomes and recovery times for kidney transplant patients.
How similar studies have performed: While the specific approach of this study may be novel, similar pharmacokinetic modeling studies in other surgical contexts have shown promise in optimizing drug dosing.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients scheduled for elective living donor kidney transplantation * end stage renal disease with oliguria or anuria * normal BMI (BMI 18.5 \~ 25) * obtained informed consent Exclusion Criteria: * patient with underlying neuromuscular disease
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Chul-Woo Jung, MD. PhD — Seoul National University Hospital
- Study coordinator: Chul-Woo Jung, MD. PhD
- Email: spss@dreamwiz.com
- Phone: 82-2-2072-0640
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.